ecrin-mdr-crcClinical2021Colorectal cancerColorectal CancerInterventionalhttps://newmdr.ecrin.org/Study/2707319China7ECRIN MDRRecruitingfalseFirst-line treatment of mCapOX plus cetuximab versus mFOLFOX6 plus cetuximab for metastatic left-sided CRC patients with wild-type RAS/BRAF genes: a multicenter, randomised, phase 2 studyInterventions: Experimental groupA:mCapOX+ Cetuximab;Experimental groupB:mFOLFOX6+ Cetuximab Primary outcome(s): Progression free survival;Progression free survival Study Design: Parallel2021-07-152707319ChiCTR2100047220